Tumors were harvested and processed using
Collagenase I and
DNase I (Wako, Osaka, Japan). The resulting cell suspensions were clarified using 40-μm filters to prepare single cell suspensions, and single cells were suspended in PBS supplemented with 2% FBS. Splenocytes were hemolyzed and incubated with
anti-CD16/32 2.4G2 (BD Biosciences, San Jose, CA, USA) to reduce FcγR binding. Cell-surface antigens were stained with antibodies specific for CD8 (BioLegend, San Diego, CA, USA, clone 53-6.7), CD4 (BioLegend, clone GK1.5), CD45 (BioLegend, clone 30-F11),
IA/IE (BD Bioscience, clone M5/114),
CD11c (BD Bioscience, clone HL3),
CD11b (BioLegend, clone M1/70), and
F4/80 (BioLegend, clone BM8).
For intracellular staining, cells were fixed and permeabilized using
Foxp3/Transcription Factor Staining Buffer Set (eBioscience, San Diego, CA, USA) after cell surface staining and were stained with labeled antibodies against the intracellular molecules foxp3 (eBioscience,
clone FJK-16s), glucose transporter 1 (GLUT1, Abcam, Cambridge, UK, clone EPR3915), and hexokinase II (HX2, Abcam, clone EPR20839).
Samples were analyzed on a
FACS Calibur HG flow cytometer (BD Biosciences). Data analysis was performed with
CellQuest™ software (Becton Dickinson, Lincoln Park, NJ, USA).
Tomita M., Yasui H., Higashikawa K., Nakajima K., Takakura H., Shiga T., Kuge Y, & Ogawa M. (2018). Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Research, 8, 82.